SERPINE1 and pulmonary fibrosis: These findings, in conjunction with the drug’s effectiveness in two distinct murine models, support the development of MDI-2517 for the treatment of lung fibrosis, and its entry into phase 1 clinical studies (NCT06453824) suggest it is time to move PAI-1 antagonism from the bench to the bedside.